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Abstract
The rapid decline in the cost of dense genotyping is paving the way for new DNA sequence-based
laboratory tests to move quickly into clinical practice, and to ultimately help realize the promise of
‘personalized’ therapies. These advances are based on the growing appreciation of genetics as an
important dimension in science and the practice of investigative pharmacology and toxicology. On
the clinical side, both the regulators and the pharmaceutical industry hope that the early
identification of individuals prone to adverse drug effects will keep advantageous medicines on
the market for the benefit of the vast majority of prospective patients. On the environmental health
protection side, there is a clear need for better science to define the range and causes of
susceptibility to adverse effects of chemicals in the population, so that the appropriate regulatory
limits are established. In both cases, most of the research effort is focused on genome-wide
association studies in humans where de novo genotyping of each subject is required. At the same
time, the power of population-based preclinical safety testing in rodent models (e.g., mouse)
remains to be fully exploited. Here, we highlight the approaches available to utilize the knowledge
of DNA sequence and genetic diversity of the mouse as a species in mechanistic toxicology
research. We posit that appropriate genetically defined mouse models may be combined with the
limited data from human studies to not only discover the genetic determinants of susceptibility,
but to also understand the molecular underpinnings of toxicity.
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One of the goals of mechanistic toxicology is the discovery of the biochemical mechanisms
underlying toxicity responses in humans. This research leads to the discovery of genes and
polymorphisms responsible for toxicity and an understanding of how molecular pathways
are altered in response to xenobiotic exposure. Recent advances in high-throughput methods
of gathering biological data and in computational power to manipulate these datasets has
changed the manner in which this research can be conducted. While toxicology will always
rely upon systematic in vitro and in vivo investigation of model systems, the generation of
new hypotheses regarding the genetic causes of toxicity has benefited greatly from the
sequencing of mammalian genomes and the invention of gene-expression microarrays. The
sequencing of several mammalian genomes, including mouse [1] and human [2], has opened
up new methods for investigating the genetic basis of toxicity responses. Gene-expression
microarrays have produced a global view of transcriptional changes in response to
xenobiotic exposure and have supported the discovery of gene clusters, which may be part
of the same biological pathway, that are related to injury. The combination of these two
developments has opened up new approaches to the understanding of toxicity as it is
affected by genetic variability [3].
Finding the associations between genes & complex traits: a preponderance
of the human-centric approach
Recent advances in technologies that permit human genome-wide association studies
(GWAS) with more than 1 million SNP have enabled the identification of genetic variants
associated with important diseases [4]. In the past few years, more than 400 GWAS studies
have been published, establishing a knowledge base that links hundreds of genetic variants
to complex human diseases, as well as providing valuable insights into the complexities of
their genetic architecture [5]. These studies have not been as successful as hoped for in the
prediction of individual risk for developing a disease, but have been successful for
identifying plausible molecular causes underlying polygenic diseases and traits. It is
noteworthy that GWAS have ‘found’ many genes that have been known to be important in
the pathogenesis of the relevant diseases [6].
With regards to adverse drug reactions, a number of important advances have also been
made over the past decade with the help of GWAS approaches [7]. GWAS have identified
gene targets for approved drugs, including thiazolidine diones and sulfonylureas, statins and
estrogens [8,9]. The association between MHC alleles, especially HLA-B*5701, and
susceptibility to adverse drug reactions manifesting through a diverse set of clinical
phenotypes is one of the most intriguing stories in pharmacogenomics [10-12]. Genetic
screening is now advised or recommended for a number of drugs on the market with known
adverse drug reactions, and the introduction of new clinical tests is likely to intensify as the
ongoing trials make their way to peer review [13].
Although GWAS are increasingly popular and affordable, they present a number of
formidable logistical and technical challenges to the conduct of the studies and in the
interpretation of the results [4]. These include the challenge of selecting a well-defined
disease or trait suitable for analysis, the requirement for sufficiently large sample sizes, and
the fact that most common variants, individually or in combination, confer relatively small
increments in risk (up to 1.5-fold) and explain only a small proportion of heritability [5,14].
Human-only GWAS are also likely to remain expensive in terms of recruitment and
characterization (both phenotyping and genotyping) of the study cohorts.
The limitations of human GWAS studies may be alleviated, at least partially, by the use of
appropriate genetically-defined model systems. Cell-based models have been extensively
used in preclinical drug development for years as a means to evaluate drug-induced toxicity
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or to identify interactions of target compounds with drug-metabolizing enzymes and
transporter proteins. Importantly, the availability of a large bank of commercially available
and densely genotyped lymphoblastoid cell lines from the Centre d’Etude du
Polymorphisme Humain (Paris, France) and Coriell Institute for Medical Research (NJ,
USA) shows promise for in vitro pharmacogenetics research [15]. Rats are commonly used
in drug safety evaluation experiments, and the genetically diversified inbred rat strains are
being developed [16] and used for population-based toxicity testing [17]. However, among
the mammalian organism-based laboratory models, the mouse offers an unparalleled wealth
of genetic knowledge and resources, among which is a high-density SNP database
encompassing more than 8 million polymorphic loci across hundreds of inbred strains
[18,19].
Mouse genetics: a useful resource for population-based toxicology studies
Mouse genetic studies can complement many shortcomings of both in vitro and human-only
approaches in pharmacogenomics. For example, collection of tissues from a wide variety of
anatomical sites (e.g., brain and heart) or developmental stages is problematic in humans, as
are many experimental interventions. A successful GWAS analysis is more likely when the
phenotype of interest can be sensitively and specifically defined and measured, which is
usually not a limitation in a mouse system. With regards to the environmental health
sciences and toxicology, controlled exposure of people to environmental toxicants is often
ethically unacceptable, which makes it challenging to interpret genetic associations
produced in human cohorts exposed in the occupational or environmental setting without
validation in animal studies.
In vivo toxicity screens and mechanistic studies are often carried out in a single strain of
mouse [20-22]. This is done in order to fix as many variables as possible and has the benefit
of standardizing the genotype across multiple chemicals. While this approach provides
mechanistic information regarding toxicant activity in a single genetic background, the
reality of human toxicity is more complex, including both diverse genetic backgrounds and
uncontrolled environmental effects. The interpretation of the data with respect to the
population-wide effects is plagued by the largely inaccurate generalizations from a single
genome; inability to distinguish small and biologically important changes from background
variation; ineffective exploitation of reproducible genetic variation to dissect differential
response to chemical exposure; and inefficient use of defined genetic backgrounds to model
particular phenotypic profiles observed in human populations. To address these important
limitations, various animal models are being used by toxicologists to assess gene–
environment interactions and determine genetic causes of interindividual variability in
toxicity. Indeed, genetic background is an important component of toxicity responses
[23,24], and a successful in vivo approach to modeling the effects of genetic diversity on
toxicity will improve both the prediction of toxicity in humans as well as the identification
of sensitive subpopulations.
Panels of genetically defined animals that provide a fixed genotype within a particular strain
but encompass great genetic diversity across strains are being used in biomedical research
[25]. Both standard intercrosses between inbred lines of mice, and large populations of
inbred strains have been used as powerful tools for mapping quantitative trait loci (QTL).
Inbred mouse strains represent fixed, renewable genotypes that are ideally suited for system
biology approaches to improve our understanding of the mechanisms of toxicity and
discovery of new biomarkers associated with biological responses to toxicant exposure.
Panels of inbred mouse strains are also well-suited for identifying whole-genome response
signatures indicative of chemical exposure because of the large knowledge base on the
genetic lineage for hundreds of strains, and because the number and distribution of genetic
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polymorphisms among mouse strains is equal to or exceeds that in the human population
[26,27]. This approach also has the added advantage of ‘repeat testing’ in genetically
identical individuals within a given strain, yielding important information regarding
reproducibility of the response.
When a research study into the genetic basis of toxicity is initiated, the responsible genes
being sought could lie anywhere in the genome. A forward genetics approach, in which the
genetic basis of toxicity is investigated, is a reasonable approach to this problem. The first
step is to search for evidence that the responsible genes lie in certain chromosomal regions
by detecting correlations between the toxicity phenotype and genotype at loci throughout the
genome. This is often carried out using QTL mapping [28,29]. This involves selecting or
breeding a genetically segregating population, such as a backcross or intercross between two
inbred parental strains that demonstrate quantitative variation in the toxicity phenotype of
interest. The quantitative phenotype, such as liver histology score or serum alkaline
aminotransferase levels, is measured in each individual, who is then genotyped at a number
of genetic markers across the genome. A statistic of association, such as a likelihood ratio
statistic or a linear model, is then calculated between the phenotypic values and each
marker.
Using the ‘mouse model of the human population’ in translational clinical
research
The diversity of the genotypes archived in different inbred mouse strains is ideally suited to
identify and dissect genetic susceptibility in responses to toxicant exposure. To advance the
understanding of health risks posed by toxicants, and the role that genetic diversity plays in
determining the variability of responses between individuals and species, panels of inbred
mouse strains can be used to demonstrate the benefits afforded by combining mechanistic
toxicology with genetics.
A translational study, whereby candidate genes for susceptibility to toxicant-induced liver
injury were discovered in a mouse population and subsequently validated in two
independent human cohorts, was recently demonstrated using a well-known liver toxicant,
acetaminophen [30]. A traditional ‘human-only’ approach to a genome-wide
pharmacogenetic investigation into the genetic factors linked to liver toxicity of
acetaminophen would require a much larger number of individuals to overcome statistical
power limitations [31]. Conversely, a so-called ‘candidate gene’ analysis [10] is equally
challenging owing to the complexity of the mechanism of toxicity and the inherent biases in
candidate gene selection [32]. By utilizing a mouse model for acetaminophen-induced liver
toxicity, whole-genome association analysis and targeted sequencing, polymorphisms in
Ly86, Cd44, Cd59a and Capn8 were identified that correlate strongly with liver injury [30].
Furthermore, these candidates were validated in two independent human cohorts where
volunteers were exposed to the maximum recommended doses of acetaminophen. This study
demonstrated that variation in the orthologous human gene, CD44, is associated with
susceptibility to acetaminophen. Interestingly, well-characterized genes known to be
essential for acetaminophen toxicity did not correlate with liver injury in the panel of mouse
strains. This finding suggests that while a priori knowledge of the toxicant’s mode of action
can be useful in the selection of genes for follow-up analysis, validation of susceptibility-
modulating genes in the laboratory is essential. This finding also illustrates the important
difference between genes involved in mechanistic pathways leading to toxicant-induced
injury and genes whose variants contribute to interindividual differences in susceptibility to
toxicity, two areas that have potentially different gene sets.
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It is noteworthy that the top candidate genes derived from the analysis of the mouse
population were related to the immune response, and not to metabolism and detoxification
of acetaminophen. Interestingly, in several cytokine knockout mouse studies of
acetaminophen toxicity, the sensitivity to liver necrosis was also largely independent of
glutathione depletion [32]. The traditional view on the mechanisms of toxicity, the approach
widely utilized to predict individual responses to toxicants, would imply that the metabolism
of acetaminophen to the reactive electrophile and/or its subsequent detoxification by
glutathione conjugation should explain, at least to a considerable degree, the variability in
responses. However, no apparent correlation between the levels of major metabolizing
enzymes, glutathione, or acetaminophen plasma levels and liver injury was observed in the
mouse population. Similarly, no correlation with sensitivity for polymorphisms in the genes
encoding catalase or CYP2E1 was found, implying that variation at these key mediators of
acetaminophen toxicity probably do not contribute to differential susceptibility.
It is worth noting that the variations in drug exposure and metabolism profile have been
shown to be common causes of difference in adverse effects of chemicals across species and
strains. For example, the well-described human interindividual variability in the metabolism
of warfarin, specifically the generation of 7-hydroxywarfarin, was reproduced in a panel of
inbred mouse strains [33], and it was determined that the phenotypic differences were
associated with the polymorphisms in the Cyp2c locus. In addition, a study that used liver
microsomes isolated from the panel of mouse strains demonstrated that genetic variation in
Cyp2b9 and Ugt1a loci played a role in the oxidative metabolism of α-hydroxytestosterone
and glucuronidation of irinotecan, respectively [34]. Thus, it should be emphasized that
exposure levels should always be assessed when using populations of strains for genetic
biomarker identification.
Not every adverse drug effect in humans may be genotype dependent; thus, a multistrain
approach may also prove useful for understanding genotype-independent toxicity responses
and facilitate the identification of novel targets of therapeutic intervention that will be
effective in the entire population. When liver gene-expression levels were assessed across
strains exposed to acetaminophen, it was determined that the genes associated with the level
of liver necrosis, independent of the genetic background, were involved in cell death
pathways and form a closely linked molecular network [35]. This finding confirms a central
role for cell death-inducing intracellular cell signaling in acetaminophen-induced liver
toxicity [32,36].
The power of mouse-to-human translation studies that use mouse genetic tools has also been
shown through the QTL analysis of pulmonary responses to the air pollutant ozone. Ozone
causes highly reproducible changes in pulmonary function in humans, and significant
interindividual variation in the responses have suggested that genetic background is an
important determinant of susceptibility to ozone-induced toxicity [37]. Similarly, significant
variation in ozone-induced pulmonary injury and inflammatory responses has been found
among inbred strains of mice [38-40]. Both F2 and backcross studies utilizing differentially
responsive strains were used to discover a number of candidate QTLs for responsiveness to
ozone [38,39]. These QTLs guided the selection of the candidate genes and loci for
validation not only in subsequent mouse studies [41-43], but two homologs of the mouse
susceptibility genes (TNF and HLA-DR) have also been associated with response to ozone in
humans [44,45]. Similar QTL mapping approaches have been used to investigate many
clinical phenotypes, including alcohol-related behavior [46], alcohol metabolism [47] and
iron transport [48].
These studies indicate that the use of an inbred mouse strain panel may be a useful tool for
understanding the mode of action of toxic agents and the identification of nodes in the
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complex molecular events that may confer susceptibility to adverse events. When genotype-
dependent chemical-induced toxicity in human population is identified or suspected, this
approach has several benefits. First, potential genetic biomarkers may be developed to
prescreen individuals prior to therapeutic drug treatment when potential adverse drug events
are suspected. If the genes associated with differential susceptibility to toxicity are identified
in a preclinical phase, the subsequent pharmacogenetics research may be focused on a few
candidates to help overcome the challenge of small cohort size in human studies and to
shorten the validation period. The data acquired with this model could therefore be
influential in the analysis of individual risk to chemicals and may facilitate both drug
development and human safety endeavors. At the same time, such an approach may not be
fruitful in safety assessment of experimental drug candidates for which the risk in humans
has yet to be determined.
Second, the genetic variation among individuals is reflected in variation in gene-expression
levels [49,50], which introduces additional challenges into toxicology research on
biomarkers of effect. While major research efforts are seeking genetic and genomic markers
that could identify individuals susceptible to toxicity, less attention is given to the fact that
genetic control of gene expression may present a challenge for finding robust population-
wide expression biomarkers of toxicity responses [35]. Indeed, it is seldom appreciated in
the analysis of gene-expression data that the genetic difference between individuals is by far
the strongest effect on global gene expression at both basal levels and even when a
considerable amount of tissue damage is present [35]. Thus, a careful evaluation of gene-
expression-based biomarkers of response through multistrain experiments can avert the risk
of mistakenly identifying large genotype effects in a particular strain of animals used for
toxicity testing as the effects of treatment.
Translating SNP/gene associations into the mode of action paradigm
Determining which of the multitude of variants carried by an individual are responsible for a
given phenotype represents a massive task, especially if the causal alleles are relatively
anonymous in terms of known functional consequences. The best approaches for combining
functional credibility and statistical support in the evaluation of such variants remain to be
determined. GWAS tend to focus almost exclusively on statistical evidence and give lesser
weight to considerations of biological plausibility, but the challenges of finding causal
associations among the large number of rare variants may prompt a more careful
examination of the underlying biology [51].
Toxicogenomics has been used at all stages of chemical risk assessment, and it is thought
that gene-expression changes may be utilized as biomarkers of adverse effects [52]. Current
approaches often attempt to classify compounds with the goals of predicting adverse
responses to specific chemical classes [53], understanding the underlying biological
mechanism of toxicity [54], or identifying key nodes in the toxicity pathway that may serve
as effect biomarkers [55]. Extensive proprietary [56,57] and public [58] databases
containing gene-expression and pathological end points derived from rodent and human
tissues exposed to a variety of chemicals have been developed, thereby allowing the
scientific community to mine the data for biomarkers.
Gene expression QTL (eQTL) mapping is one of the modern tools that support the
evaluation of associations between transcript expression and genotype in order to find
genomic locations that are likely to regulate transcript expression. The availability of gene-
expression and high-density genotype data has enabled eQTL mapping in animal and human
populations. These analyses have contributed significantly to our understanding of the
effects that genetic polymorphisms may have on interindividual variability in normal
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physiological processes, in multiple tissues, and in both animals and humans [50-61].
Furthermore, these studies have shown that genetic regulation of gene expression is a key
contributor to population diversity, and is being realized not only through transcription
factors and subtle variations in sequence of their response elements, but also through
previously unknown mechanisms. While eQTL mapping is clearly an important new frontier
in the application of ’omics technologies to biomedical research, no current approaches are
available for the evaluation of the potential role of eQTLs in the response to environmental
exposures or the pathogenesis of common diseases.
Early eQTL studies surveyed natural variation in crosses of model organisms such as
budding yeast [62,63] and mouse [49]. In the mouse, two inbred parental stains were
selected and bred in either a backcross or intercross design. All progeny mice are genotyped
at a density sufficient to distinguish all recombination blocks, and microarrays were used to
measure transcript expression. Previous studies reported significant numbers of eQTL (~9%
of the transcripts surveyed) and demonstrated that there are genomic loci that contain more
eQTL than expected by chance. These eQTL ‘hotspots’ are thought to regulate the
expression levels of dozens of transcripts [49] and have been observed in several tissues in
the mouse [49,50,59]. By examining the genes that lie beneath the eQTL hotspot,
investigators can propose regulatory candidates for the transcripts with eQTL at the hotspot.
eQTL studies also commonly identify both cis-acting eQTL [64], for which a transcript’s
eQTL is located near the transcript itself in the genome, and trans-acting eQTL, for which a
transcript’s eQTL is located far from the transcript. It has been hypothesized that cis-eQTL
are caused by polymorphisms in regulatory regions close to the transcript itself, whereas
trans-eQTL are caused by polymorphisms in distant genes that affect transcript expression,
either directly or indirectly, in an allele-specific manner.
Indeed, while the study of individual genes is informative and can improve our
understanding of the causes of differential toxicity in populations, a broader approach that
focuses on gene networks and biological pathways may produce more interpretable results.
eQTL mapping can be used to generate hypotheses regarding transcriptional regulation and
can be integrated with gene coexpression data to discover gene networks or pathways that
are associated with a clinical trait. For example, transcript expression data in the livers of a
panel of C57BL/6J × DBA/2J F2 mice was combined with obesity data, and eQTL mapping
was used to identify causal gene-expression networks [65,66]. eQTL data may also be
combined with estimates of transcription factor activity to infer causal relationships between
transcription factors and clusters of eQTL genes [67]. Other methods to infer causality
between regulatory candidate genes under eQTL hotspots and the trans-regulated genes that
map to the eQTL locus have also been proposed to assist in narrowing the list of candidate
genes for further biological investigation [64,68].
Network-based approaches have been used in research into Type I diabetes and heart
disease, and have shown the power of integrating human data with data derived from mouse
models. A GWAS in a large human population proposed the receptor typrosine kinase
ERBB3 as the best candidate gene near a QTL for Type I diabetes [69]. Separate work that
examined liver gene expression in a smaller cohort of human samples with and without
Type I diabetes found that ERBB3 did not have a cis-eQTL but that a flanking gene, RPS26,
did. Since the disease phenotype and RPS26 both had QTLs in the same location, this
suggested the RPS26 was a stronger candidate than ERBB3. The authors then used mouse
liver and adipose expression data from several mouse crosses to construct causal expression
networks for the ERBB3 and RPS26 orthologs in the mouse. They were able to show that
ERBB3 is not associated with any known Type I diabetes genes, whereas RPS26 is
associated with a network of several genes that are part of the Kyoto Encyclopedia of Genes
and Genomes (KEGG) Type I diabetes pathway [61]. This type of analysis demonstrates the
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power of combining human and mouse data with a network-based approach that has been
proposed for use in drug discovery [70] and may prove useful in toxicology studies.
It should be noted that the accuracy of cis-eQTL detection has been called into question
owing to the possibility of SNPs residing within the sequence queried by microarray probes
[64,71,72]. Microarray probes for mice are designed based on the reference sequence of
C57BL/6J. Transcripts in other strains with polymorphisms in the probe sequence will bind
with lower affinity than the C57BL/6J transcript, giving the false appearance of allele-
specific expression levels associated with the transcript location, which is the defining
characteristic of a cis-eQTL. Studies in which shorter, 25-nucleotide microarray probes are
used [71] appear to be more significantly affected than studies that use longer, 50- to 60-
nucleotide-long probes [64,72]. This is consistent with the hypothesis that a SNP within a
probe sequence will affect shorter probes more strongly than longer probes. The validity of
eQTL hotspots has also been questioned [73,74] owing to the possibility that sets of highly
correlated genes will naturally cluster over the same genomic marker. Furthermore, sets of
highly correlated genes are likely to be part of the same gene-ontology category, and so
when geneontology category enrichment is conducted on eQTL hotspots, they are likely to
(falsely) appear biologically coherent. A permutation strategy, in which the sample labels
are permuted and the expression labels are held fixed, has been suggested to address this
problem [74,75]. False eQTL hotspots may also arise owing to intersample correlation, and
a mixed-model approach has been shown to eliminate spurious eQTL hotspots in mouse data
[11].
Another matter of concern in eQTL mapping studies is how to control for the massive
multiple testing involved. There are two levels of multiple testing carried out in an eQTL
study; multiple testing across correlated SNPs and across multiple correlated transcripts.
Multiple testing across SNPs may be addressed by permuting the sample labels in the
genotype data while holding the expression data fixed [75]. Multiple testing across genes
may be addressed using approaches based on the false-discovery rate [76].
Conclusion & future perspective
Recognition of the challenges of currently available laboratory animal-based genetics
resources led to the realization that a new general-purpose mouse population was needed to
model complex human diseases, with particular emphasis on traits relevant to human health
in its broadest aspects. Open discussion among members of the genetics community resulted
in the conception and design of the ‘Collaborative Cross’ (CC) [77,78]. Establishment of
this new mouse-based resource will considerably expedite gene discovery and
characterization and serve as a powerful complement to ongoing studies in human genetics.
The CC provides a translational platform for systems genetics that integrates classical
genetics and systems biology tools to identify genetic networks that underlie complex
phenotypes. A pre-requisite for systems genetics is a realistic experimental population
structure, which is essential to unravel the complex biological processes that may differ
from one individual to another, such as cancer susceptibility or the response to an
environmental exposure. The CC population was created through a community effort by the
Complex Trait Community [101]. This resource will obviate the need for researchers to
produce ephemeral backcross or F2 populations; it will need to be genotyped only once; it
will archive thousands of recombination events and millions of genetic polymorphisms; and
it will facilitate international and intergenerational comparisons of genetic effects.
The CC satisfies four essential criteria for an optimal experimental platform that can support
systems genetic studies [79]:
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▪ Genome-wide genetic variation;
▪ Randomization of the genetic variation;
▪ It is infinitely reproducible;
▪ It is sufficiently large to support statistical analysis of the data.
The overall design of CC consists of eight founder strains (A/J, C57BL/6J, 129S1/SvImJ,
NOD/LtJ, NZO/HiLtJ, CAST/Ei, PWK/PhJ and WSB/EiJ) bred through an eight-way
‘funnel’ breeding design established to randomly mix the variation present in the founder
strains before inbreeding by brother–sister mating. The founder strains were selected from a
set of over 100 strains in order to maximize genetic diversity and utility for studying traits of
widespread interest. The eight CC founder strains capture approximately 90% of the known
allelic diversity across all 1-Mb intervals spanning the entire mouse genome; compare this
with AXB/BXA and BXD, the two most commonly used mouse recombinant inbred panels,
which each capture only approximately 13% of the known variation, with much of it
overlapping [27]. Furthermore, the population of emergent CC lines has a much more
random distribution of genetic variation than existing panels of inbred strains such as the
mouse phenome panel [80,81], which has considerable genetic linkage across chromosomes
that result in high rates of false-positive associations. Since the CC strains have a population
structure that randomizes existing genetic variation, this resource will provide unparalleled
power to assign causality to understand the intricacies of biological networks underlying
disease and toxicant response. The types, distribution and frequency of genetic
polymorphisms are close to those in human populations, and the fraction of genetic diversity
captured in CC lines is far superior compared with other commonly used mouse populations.
Importantly, preliminary phenotypic characterization of pre-CC strains indicates that a very
large variability exists within the CC population following changes in environmental
conditions (e.g., diet and exercise). The recombination, inbreeding rates and statistical
power of this novel cross has been examined by others and found to be optimal for systems
genetics applications [82,83].
Executive summary
▪ Genome-wide association studies in human cohorts, large and small, provide
important information on the genetic causes of complex diseases, individual
susceptibility to chemical exposures and other environmental factors. Still, the
validation of the ‘candidate’ genes and/or polymorphisms is a daunting task that is
compounded by the statistical challenges in defining the candidates.
▪ Additional resources for gene/polymorphism discovery are available through in
vitro experiments with densely genotyped human cell lines assembled into cohorts or
familial structures, or in vivo approaches capitalizing on the knowledge of mouse
genetics and the availability of densely genotyped reproducible panels of strains.
▪ Several proof-of-concept studies that utilized the ‘mouse model of the human
population’ to advance translational clinical research have been published recently.
This work points to the promise of the combination approach whereby human
disease or toxicity can be modeled in animals and lead to the discovery of candidates
for validation in human cohorts.
▪ Translation of gene/polymorphism associations between species also provides the
opportunity to better understand which nodes in the complex mode of toxicity/
disease pathogenesis pathways are most likely to be causes of genetic diversity in
responses. Such knowledge will empower the practical use of the genetic
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information for individualized therapy and/or assessment of risk from environmental
exposures.
▪ The ‘Collaborative Cross’ is a new mouse-based resource that will considerably
expedite gene discovery and characterization, and serve as a powerful complement
to ongoing studies in human genetics.
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